A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
for Solid Tumor
11 locations incl. San Francisco
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT06952010·Phase 1·Recruiting·Listed Apr 2025